Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase Ⅱ Trial.
Yihebali ChiXiangqian ZhengYuan ZhangFeng ShiYing ChengZhuming GuoMing-Hua GeJianwu QinJiewu ZhangZhendong LiXiaohong ZhouRui HuangXiao-Hong ChenHui LiuRuochuan ChengZhengang XuDapeng LiPingzhang TangMing GaoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Anlotinib demonstrated promising efficacy and favorable tolerance in the treatment of locally advanced or metastatic RAIR-DTC, supporting further research to establish its role in the treatment of this serious disease.